Focused on patients
The patients we serve around the world are able to lead better lives. Patients inspire the work we do every day.
Annual General Shareholders’ Meeting 2023 – June 16, 2023 - 2nd call – Expected to be held on this date / June 15, 2023 - 1st call. Click here.
Plasma, the liquid part of blood, contains proteins and other components of incalculable therapeutic value. From this essential life fluid, Grifols develops medicines to treat patients around the world living with chronic and rare diseases that can be life-threatening.
We combine our vast knowledge and longstanding excellence in plasma with new technology platforms to accelerate the development of novel plasma and non-plasma treatments.
The patients we serve around the world are able to lead better lives. Patients inspire the work we do every day.
IMMUNOLOGY / INFECTIOUS DISEASES
HEPATOLOGY / INTENSIVE CARE
PULMONOLOGY
HEMATOLOGY
NEUROLOGY
Grifols’ vertically integrated production process guarantees the highest standards of quality and safety, from initial donation to final delivery of medicines to the patient.
Plasma donations undergo a long and complex manufacturing process that ensures the quality and safety of plasma-derived medicines.
We combine our longstanding plasma excellence with new technology platforms to accelerate the development of novel treatments.
Grifols is increasingly diversifying its therapeutic approach with a portfolio of innovative non-plasma treatments such as a new class of recombinant protein candidates and small-molecule pharmaceuticals.
We develop, produce and market innovative medicines, solutions and services in more than 110 countries.